Products Revefenacin was approved in the United States in 2018 as a monodose inhalation solution (Yupelri). The active ingredient belongs to the LAMA group. Structure and properties Revefenacin (C35H43N5O4, Mr = 597.8 g/mol) exists as a white crystalline powder and is sparingly soluble in water. It has an active metabolite formed by hydrolysis. Effects Revefenacin … Revefenacin
Products Glycopyrronium bromide is commercially available in the form of hard capsules with a powder for inhalation (Seebri Breezhaler). It was approved in the EU in 2012 and in many countries in April 2013. Glycopyrronium bromide is also combined fixed with indacaterol (Ultibro Breezhaler, approved in many countries in 2014). In 2020, a combination of … Glycopyrronium Bromide
Products Tiotropium bromide is commercially available in the form of capsules for inhalation and has been approved since 2002 (Spiriva). The capsules are inhaled using the Spiriva HandiHaler. The inhalation solution (Spiriva Respimat) was approved in many countries in 2016. Tiotropium bromide is the successor to ipratropium bromide (Atrovent, both Boehringer Ingelheim). In 2016, a … Tiotropium Bromide
Products Umeclidinium bromide is commercially available as a powder for inhalation as a monopreparation (Incruse Ellipta) and as a fixed combination with vilanterol (Anoro Ellipta, LAMA–LABA combination). It was approved in many countries in 2014. In 2017, a combination of umeclidinium bromide, fluticasone furoate, and vilanterol was released in the EU (Trelegy Ellipta), and in … Umeclidinium Bromide
Products Aclidinium bromide is commercially available as a powder inhalation (Bretaris Genuair, Eklira Genuair). It is administered with the Genuair inhaler and was approved in the EU and US in 2012. In many countries, it entered the market in 2013. In the EU, a fixed-dose combination with formoterol was released in 2014 (Brimica Genuair). Structure … Aclidinium Bromide
